恶性肿瘤患者化疗后骨髓抑制影响因素的分析

恶性肿瘤患者化疗后骨髓抑制影响因素的分析

方甜甜,杨彦玲,宋沧桑,雷博媛

昆明市第一人民医院,云南省疾病预防控制中心,昆明市第一人民医院,昆明市第一人民医院

收稿日期:2017-02-24 修回日期:2017-04-26 出版日期:2017-06-25 发布日期:2017-06-26

Analysis on factors affecting bone marrow depression in cancer patients after chemotherapy

方甜甜,, and

Department of Pharmacy,Kunming First Peopls Hospital,Yunnan Kunming;China;,Yunnan center for disease control and prevention,Yunnan Kunming,,Department of Pharmacy,Kunming First Peopls Hospital,Yunnan Kunming

Received:2017-02-24 Revised:2017-04-26 Online:2017-06-25 Published:2017-06-26

摘要/Abstract

摘要： 目的：探究恶性肿瘤患者化疗后发生骨髓抑制的影响因素,为化疗前对患者进行评估提供参考依据。方法：以某三甲医院HIS为数据来源,选取2013-2015年肿瘤科接受化疗的患者216例,对其临床资料进行回顾性分析,对和骨髓抑制可能有关的所有因素进行单因素Logistic回归分析,分析后显示为有意义的因素(P＜0.05 )则再进行多因素Logistic回归分析。结果：多因素Logistic回归分析结果提示非手术(OR=3.456,95%CI:1.197-9.980),烷化剂(OR=0.065,95%CI:0.007-0.624),前白蛋白(OR=0.990,95%CI: 0.983-0.997)。结论：手术和前白蛋白可降低骨髓抑制的发生风险,烷化剂发生骨髓抑制的风险低于其他抗肿瘤药物。

Abstract: Objective: To explore the analysis on factors affecting bone marrow depression in cancer patients after chemotherapy, provide the reference for assessing cancer patients before chemotherapy ,providing a reference for the assessment of patients befor chemotherapy. Method: The research of hospital information system (HIS)data from one general hospital comprising 216 profiles of cancer patients undergoing chemotherapy was carried out. All profiles were invaluated by deferent variants, then analyze these variants with Logistic regression analysis. Results: Multivariate logistic regression analysis indicated that nonoperative treatment(OR=3.456,95%CI: 1.197 - 9.980) was independent risk factors for bone marrow depression after chemotherapy；alkylating agents(OR=0.065,95%CI:0.007-0.624)and prealbumin(OR=0.990,95%CI: 0.983-0.997)were independent protective factors for bone marrow depression after chemotherapy. Conclusion: Operative treatment and prealbumin could lower the risk of bone marrow depression after chemotherapy；alkylating agents could lower the risk of bone marrow depression after chemotherapy compared with other antitumor drugs.

方甜甜,杨彦玲,宋沧桑,雷博媛. 恶性肿瘤患者化疗后骨髓抑制影响因素的分析[J]. .

方甜甜,, and. Analysis on factors affecting bone marrow depression in cancer patients after chemotherapy[J]. .

参考文献

[1]张昊,高黎黎,李泽信.化疗对乳腺癌患者骨髓抑制的临床分析[J].中国现代普通外科进展,2012,14(8):169.
[2]谢嵩,魏长生.肿瘤化疗患者骨髓抑制发生情况调查与分析[J].中国现代应用药学,2010, 27(13):1219-1221.
[3]田同荣.恶性肿瘤患者化疗引起口腔黏膜炎的危险因素分析[J].中国肿瘤临床与康复,2012,14(2):154.
[4]朱大年等．生理学．第7版．人民卫生出版社,2012:54．
[5]Norio Suzuki , Harumi Y. Mukai , Masayuki Yamamoto. In vivo regulation of erythropoiesis by chemically inducible dimerization of the erythropoietin receptor intracellular domain[J]. PLoS One,2015,10(3)：e0119442. DOI：10.1371/journal.pone.0119442
[6]张新胜,李方方,赵丹丹,徐曼曼,程航. 失血性贫血小鼠恢复过程中骨髓基质金属蛋白酶变化[J]. 河南师范大学学报(自然科学版),2013,41(2):119-122.
[7]王大志,庄安士,张书瑜,杨晓璐. 抗肿瘤药与呼吸系统恶性肿瘤化疗患者骨髓抑制发生风险的Logistic 回归分析[J]. 药物流行病学杂志,2012,21(8):365-368.
[8]Zhu XH,Wu YF,Qiu YD,et al． Effect of early enteral combined with parenteral nutrition in patients undergoing pancreaticoduodenectomy[J]． World J Gastroenterol,2013,19 ( 35) : 5889-5896．
[9]陈文彬等．诊断学．第7版．人民卫生出版社,2012：360-361．
[10]钟海均,应杰儿,马胜林．肿瘤专用型肠内营养乳剂对胃癌患者营养状况和免疫功能的影响[J]．中华胃肠外科杂志,2006,9( 5) : 405-408
[11]李榕,马美丽,宋懿懿,等．初治晚期肺癌132 例患者营养状况调查[J]．肿瘤,2008, 28( 4) : 353-356
[12]隋杰,肖灿鹏．人血小板生成素的研究进展[J]．生物技术通讯,2002,13( 1) ∶ 76 － 82．
[13]Shimabukuro R,Kawanaka H,Tomikawa M,et al． Effect of thrombopoietin on platelet counts and liver regeneration after partial hepatectomy in a rat model[J]． Surg Today,2009,39 ( 2 ) ∶ 1054 －1059．
[14]de Sauvage FJ,Carver － Moore K,Luoh SM,et al． Physiologicalregulation of early and late stages of megakaryocytopoiesis by thrombopoietin[J]． J Exp Med,1996,183( 2) ∶ 651 － 656．
[15]朱大年等．生理学．第7版．人民卫生出版社,2012：61．